The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice
Abstract
Previous work from our laboratory showed prevention of 1‐methyl‐4‐phenyl‐1,2,3,6 tetrahydropyridine (MPTP) induced dopamine depletion in striatum of C57Bl/6 mice by 17β‐estradiol, progesterone, and raloxifene, whereas 17α‐estradiol had no effect. The present study investigated the mechanism by which these compounds exert their neuroprotective activity. The hormonal effect on the dopamine transporter (DAT) was examined to probe the integrity of dopamine neurons and glutamate receptors in order to find a possible excitotoxic mechanism. Drugs were injected daily for 5 days before MPTP (four injections, 15 mg/kg ip at 2‐h intervals) and drug treatment continued for 5 more days. MPTP induced a decrease of striatal DAT‐specific binding (50% of control) and DAT mRNA in the substantia nigra (20% of control), suggesting that loss of neuronal nerve terminals was more extensive than cell bodies. This MPTP‐induced decrease of striatal [125 I]RTI‐121 specific binding was prevented by 17β‐estradiol (2 μg/day), progesterone (2 μg/day), or raloxifene (5 mg/kg/day) but not by 17α‐estradiol (2 μg/day) or raloxifene (1 mg/kg/day). No treatment completely reversed the decreased levels of DAT mRNA in the substantia nigra. Striatal [125 I]RTI‐121 specific binding was positively correlated with dopamine concentrations in intact, saline, or hormone‐treated MPTP mice. Striatal NMDA‐sensitive [3 H]glutamate or [3 H]AMPA specific binding remained unchanged in intact, saline, or hormone‐treated MPTP mice, suggesting the unlikely implication of changes of glutamate receptors in an excitotoxic mechanism. These results show a stereospecific neuroprotection by 17β‐estradiol of MPTP neurotoxicity, which is also observed with progesterone or raloxifene treatment. The present paradigm modeled early DA nerve cell damage and was responsive to hormones. Synapse 41:131–138, 2001. © 2001 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Cited by
Gillies, G. E., & McArthur, S. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002071 · Cited by 733
Progesterone receptors: form and function in brain
Brinton, R. D., Thompson, R. F., Foy, M. R., Baudry, M., Wang, J., Finch, C. E., Morgan, T. E., Pike, C. J., Mack, W. J., Stanczyk, F. Z., et al. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2008.02.001 · Cited by 675
Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications
Brann, D. W., Dhandapani, K., Wakade, C., Mahesh, V. B., & Khan, M. M. (2007) · Steroids · doi:10.1016/j.steroids.2007.02.003 · Cited by 647
Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Rehman, M. U., Wali, A. F., Ahmad, A., Shakeel, S., Rasool, S., Ali, R., Rashid, S. M., Madkhali, H., Ganaie, M. A., & Khan, R. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180911124605 · Cited by 265
Antioxidants as treatment for neurodegenerative disorders
Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 252
Metadata
- Authors
- Callier, S., Morissette, M., Grandbois, M., Pélaprat, D., & Di Paolo, T.
- Venue
- Synapse
- Publisher
- Wiley
- Published
- 2001-05-14
- Volume
- 41
- Issue
- 2
- Pages
- 131-138
- ISSN
- 0887-4476 (ISSN-L)
- 1098-2396
- OpenAlex
- W1975941800
- Cited by
- 186
- References
- 1
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. https://app.cochat.ai/papers/10.1002/syn.1067
- The paper
- Callier, S., Morissette, M., Grandbois, M., Pélaprat, D., & Di Paolo, T. (2001). Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse. https://doi.org/10.1002/syn.1067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.